רווח נקי למניה (EPS TTM): Sol-Gel (SLGL)
Annual net income per share on the GURU.Markets chart confirms the authority of Sol-Gel Technologies (SLGL) in dermatology through innovative substance encapsulation, where -5.70 represents the latest metric reading. High business scalability is driven by patents for drug delivery systems. Stable margins and supply chains are guaranteed by efficient drug distribution logistics.
פילוחים אנליטיים ודוחות נתונים של חברת Sol-Gel Technologies Ltd (SLGL)
Institutional capital evaluates Sol-Gel Technologies (SLGL) through the lens of the real yield of each security. The dynamics of current earnings per share over the last 12 months are calculated as a rolling total of net income, excluding the impact of one-time accounting adjustments. This allows for an objective measurement of the monetization efficiency of dermatological innovations and licensing contracts. The steady growth of the line confirms the synergy of partnerships with cosmetic brands. The indicator's positive trend guarantees the stability of the asset's fundamental value.
